dr. kimberly blackwell discusses the t-dm1 emilia trial coprimary endpoints
Published 12 years ago • 295 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
1:50
dr. kimberly blackwell discusses the t-dm1 emilia trial
-
9:58
kimberly l. blackwell: primary results from emilia
-
1:38
dr. debu tripathy discusses the updated emilia trial results for t-dm1
-
11:21
dr. kimberly blackwell: treatment innovations in targeting the her-2 receptor - part 1
-
0:46
dr. kimberly l. blackwell on a promising her2 breast cancer treatment
-
1:00
dr. blackwell discusses margetuximab for her2 breast cancer
-
1:39
dr. blackwell on treatment landscape of her2 breast cancer
-
3:58
frontline t-dm1 in her2-positive metastatic breast cancer
-
19:46
metastatic breast cancer: what you need to know
-
1:20:55
treatment of metastatic breast cancer
-
6:08
first-line treatment of her2-positive metastatic breast cancer
-
0:52
dr. blackwell on emerging therapies in tnbc
-
1:15
dr. blackwell on the impact of the cleopatra and marianne studies in her2 breast cancer
-
3:03
kimberly blackwell, md: clinical trial data supporting these choices
-
1:43
dr. blackwell discusses the her2climb study in her2 breast cancer
-
2:02
kimberly blackwell, md: expectations of therapy
-
3:22
kimberly blackwell, md: expectations of therapy in breast cancer
-
2:36
dr. blackwell discusses tucatinib in her2 breast cancer
-
2:18
kimberly blackwell, md: considerations for different therapi
-
1:36
phase 3 trial investigates t-dm1 and pertuzumab in her2 breast cancer
-
6:07
dr. kimberly blackwell: treatment innovations in targeting the her-2 receptor - part 2
-
4:15
choosing therapy for hr metastatic breast cancer